BRIEF-Cyclerion Therapeutics Announces Progress Toward Cyc-126 Phase 2 Proof-Of-Concept Study With FDA Feedback

Reuters02-17

BRIEF-Cyclerion <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Progress Toward Cyc-126 Phase 2 Proof-Of-Concept Study With FDA Feedback

Feb 17 (Reuters) - Cyclerion Therapeutics Inc CYCN.O:

CYCLERION THERAPEUTICS ANNOUNCES PROGRESS TOWARD CYC-126 PHASE 2 PROOF-OF-CONCEPT STUDY WITH FDA FEEDBACK AND FORMATION OF CLINICAL ADVISORY BOARD
CYCLERION THERAPEUTICS INC - ON TRACK TO INITIATE PHASE 2 STUDY IN 2026

Source text: ID:nGNX4Jz68W

Further company coverage: CYCN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612454533?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612454533","market":"us","top_or_hot":-1,"title":"BRIEF-Cyclerion Therapeutics Announces Progress Toward Cyc-126 Phase 2 Proof-Of-Concept Study With FDA Feedback","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cyclerion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Progress Toward Cyc-126 Phase 2 Proof-Of-Concept Study With FDA Feedback </title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span>Cyclerion Therapeutics Inc <span>CYCN.O</span>:</p><ul><li><p>CYCLERION THERAPEUTICS ANNOUNCES PROGRESS TOWARD CYC-126 PHASE 2 PROOF-OF-CONCEPT STUDY WITH FDA <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> AND FORMATION OF CLINICAL ADVISORY BOARD</p></li><li><p>CYCLERION THERAPEUTICS INC - ON TRACK TO INITIATE PHASE 2 STUDY IN 2026</p></li></ul><p>Source text: <span>ID:nGNX4Jz68W</span></p><p>Further company coverage: <span>CYCN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cyclerion Therapeutics Announces Progress Toward Cyc-126 Phase 2 Proof-Of-Concept Study With FDA Feedback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cyclerion Therapeutics Announces Progress Toward Cyc-126 Phase 2 Proof-Of-Concept Study With FDA Feedback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-17 20:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cyclerion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Progress Toward Cyc-126 Phase 2 Proof-Of-Concept Study With FDA Feedback </title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span>Cyclerion Therapeutics Inc <span>CYCN.O</span>:</p><ul><li><p>CYCLERION THERAPEUTICS ANNOUNCES PROGRESS TOWARD CYC-126 PHASE 2 PROOF-OF-CONCEPT STUDY WITH FDA <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> AND FORMATION OF CLINICAL ADVISORY BOARD</p></li><li><p>CYCLERION THERAPEUTICS INC - ON TRACK TO INITIATE PHASE 2 STUDY IN 2026</p></li></ul><p>Source text: <span>ID:nGNX4Jz68W</span></p><p>Further company coverage: <span>CYCN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA9DWPGV:1","article_id":"2612454533","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612454533","pubTimestamp":1771331312,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cyclerion Therapeutics Announces Progress Toward Cyc-126 Phase 2 Proof-Of-Concept Study With FDA Feedback Feb 17 (Reuters) - Cyclerion Therapeutics Inc CYCN.O:CYCLERION THERAPEUTICS ANNOUNCES PR","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CYCN":"Cyclerion Therapeutics, Inc."},"translate_title":"简介-Cyclerion Therapeutics宣布CYC-126 2期概念验证研究取得进展并获得FDA反馈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYCN":0.9},"content_text":"BRIEF-Cyclerion Therapeutics Announces Progress Toward Cyc-126 Phase 2 Proof-Of-Concept Study With FDA Feedback Feb 17 (Reuters) - Cyclerion Therapeutics Inc CYCN.O:CYCLERION THERAPEUTICS ANNOUNCES PROGRESS TOWARD CYC-126 PHASE 2 PROOF-OF-CONCEPT STUDY WITH FDA FEEDBACK AND FORMATION OF CLINICAL ADVISORY BOARDCYCLERION THERAPEUTICS INC - ON TRACK TO INITIATE PHASE 2 STUDY IN 2026Source text: ID:nGNX4Jz68WFurther company coverage: CYCN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612454533","isCrawlerRequest":true}